MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY:XLV)

161.21 -0.59 (-0.36%)
Streaming Delayed Price Updated: 3:56 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
News headline image
Leading And Lagging Sectors For July 16, 2026 ↗
Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLV) State Street Health Care Select Sector SPDR ETF 160.00 1.71 1.08 33.2K (NYSE:XLP) State Street Consumer Staples Select Sector SPDR 
Via Benzinga
Topics ETFs
News headline image
Leading And Lagging Sectors For July 13, 2026 ↗
Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLE) State Street Energy Select Sector SPDR ETF 55.8609 0.781 1.41 305.4K (NYSE:XLV) State Street Health Care Select Sector SPDR 
Via Benzinga
Topics ETFs
News headline image
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
Leading And Lagging Sectors For July 7, 2026 ↗
Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLV) State Street Health Care Select Sector SPDR ETF 163.9673 2.007 1.23 70.3K (NYSE:XLP) State Street Consumer Staples Select Sector SPDR 
Via Benzinga
Topics ETFs
News headline image
State Street Health Care ETF Tops Invesco Pharma on Cost and Size ↗
Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income. 
Via The Motley Fool
Topics ETFs
News headline image
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗
Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
Leading And Lagging Sectors For July 1, 2026 ↗
Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLC) State Street Communication Services Select Sector SPDR ETF 108.900 1.770 1.65 18.2K (NYSE:XLV) State Street Health Care Select Sector... 
Via Benzinga
Topics ETFs
News headline image
Leading And Lagging Sectors For June 23, 2026 ↗
Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLP) State Street Consumer Staples Select Sector SPDR ETF 83.2775 1.097 1.33 51.0K (NYSE:XLV) State Street Health Care Select Sector SPDR 
Via Benzinga
Topics ETFs
News headline image
Health Care ETFs: XLV Delivers Low Fees and Solid Returns ↗
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Giants or Medical Innovators? XLV and PINK Are Built for Different Investors. ↗
One fund backs medical breakthroughs and charity, while the other favors industry giants and steady income. Compare their strategies and portfolio makeup. 
Via The Motley Fool
Topics ETFs
News headline image
State Street's Health Care ETF Tops Invesco's on Yield and Returns ↗
Expense ratios, dividend yields, and risk profiles set these healthcare ETFs apart. See how their strategies shape long-term performance for investors. 
Via The Motley Fool
Topics ETFs
News headline image
Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV ↗
Expense ratios match, but portfolio breadth, yield, and stock concentration set these two healthcare ETFs apart for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗
The healthcare sector outperformed the rest of the market over the past week. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
These Stocks Could Be the Biggest Winners of the 2026 Midterms ↗
Defense, healthcare, and financial stocks may outperform ahead of midterm elections as investors position for policy shifts 
Via MarketBeat
Topics Economy Stocks
News headline image
1 No-Brainer Healthcare Vanguard ETF to Buy Right Now for Less Than $1,000 ↗
Healthcare stocks have been laggards for a while now. The current economic slowdown and structural tailwinds make it much more attractive now. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Balancing Act: U.S. Gender Labor Gap Closes for the First Time in History
The long-standing "gender gap" in the American workforce has effectively closed. According to the Bureau of Labor Statistics (BLS) report released for the first quarter of 2026, the participation rate... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
What Q1 Earnings Could Mean for the S&P 500 Uptrend ↗
Via MarketBeat
Topics Stocks
News headline image
Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now ↗
AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
The S&P 500's 3 Best-Performing Stocks so far in 2026 ↗
Via MarketBeat
Topics Stocks
News headline image
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗
In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six... 
Via Stocktwits
News headline image
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional... 
Via MarketMinute
Topics Artificial Intelligence ETFs
News headline image
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗
The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? ↗
CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market. 
Via Stocktwits
News headline image
Why Did IXHL Stock Tank Over 32% Today? ↗
The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 
Via Stocktwits
News headline image
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗
The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp. 
Via Stocktwits
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12. 
Via Stocktwits
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings. 
Via Stocktwits
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story